Targeted radiation therapy for brain lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new targeted radiation therapy for lymphoma that has spread to the brain or spinal cord and has not responded to other treatments. The treatment uses a radioactive molecule (yttrium-90) attached to a substance that homes in on a specific marker (CXCR4) on the lymphoma cells, aiming to destroy them while limiting damage to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lymphoma that started in the brain or spinal cord (primary CNS lymphoma) or spread there from elsewhere (secondary CNS lymphoma), and it has come back or not responded to treatment.
- You have at least one tumor spot in the brain or spinal cord covering that can be seen on a scan.
- You have had a special PET scan (called PentixaFor) within the last 2 months that shows your tumor cells have a certain marker (CXCR4).
- You have your own stem cells saved (stored) for a possible transplant.
- Your blood counts and kidney/liver function are within safe ranges for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial studies how newly diagnosed primary central nervous system (brain) non-Hodgkin lymphoma responds to a specific type of radiation to the whole brain, and it also looks at changes in thinking, mood, and behavior. It may help doctors understand how this treatment affects day-to-day brain function.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.